ReviewAJR. American journal of roentgenology2012
Molecular imaging of prostate cancer: PET radiotracers.
Review in AJR. American journal of roentgenology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer withJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Trial
- Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.European urology oncology · 2019Trial
- Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2013Trial
- Not always a perfect match: discrepancies between PSMA PET/CT and MRI in prostate cancer diagnosis and staging.Abdominal radiology (New York) · 2026Review
- Review
- Role of PSMA PET/CT in imaging and management of prostate cancer.Current opinion in oncology · 2025Review
- Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.Journal of Zhejiang University. Science. B · 2025Review
- From biology to the clinic - exploring liver metastasis in prostate cancer.Nature reviews. Urology · 2024Review
- Diagnostic Accuracy of Molecular Imaging Techniques for Detecting Prostate Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2024Review
- An Overview of In Vitro Assays ofDiagnostics (Basel, Switzerland) · 2023Review
- Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.Cancers · 2021Review
- Application-specific nuclear medicalPhysics in medicine and biology · 2021Review
- Effects of administration route on uptake kinetics ofScientific reports · 2021Article
- The Evolving Role ofFrontiers in oncology · 2021Article
- A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Review
- Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria.Theranostics · 2020Article
- Safety Profile and Therapeutic Efficacy of One Cycle of Lu177-PSMA in End-Stage Metastatic Castration-Resistant Prostate Cancer Patients with Low Performance Status.Nuclear medicine and molecular imaging · 2019Article
- Preclinical evaluation of aAmino acids · 2019Article
- Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer.Cancer reports (Hoboken, N.J.) · 2019Review
- Treatment Response Assessment of Skeletal Metastases in Prostate Cancer withNuclear medicine and molecular imaging · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
objectiveRecent advances in the fundamental understanding of the complex biology of prostate cancer have provided an increasing number of potential targets for imaging and treatment. The imaging evaluation of prostate cancer needs to be tailored to the various phases of this remarkably heterogeneous disease.
conclusionIn this article, I review the current state of affairs on a range of PET radiotracers for potential use in the imaging evaluation of men with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.